Now that Eli Lilly is looking to create a closed-loop system for diabetes management, does that mean this product will soon be available?
Diabetes
Latest News
Advertisement
CME Content
Advertisement
The cornerstone of working with patients is sharing decision-making and presenting information in a way that helps patients understand the risks and benefits of various choices.
HMG-CoA reductase inhibitors are a class of lipid-lowering medications. Here is a look at guidelines and studies for health care professionals.
Top articles of the week from The American Journal of Pharmacy Benefits.
Liver cancer is the most common cancer caused by diabetes and obesity.
Ademlog (insulin lispro injection) approved to control blood glucose levels among patients with diabetes.
Updated diabetes treatment guidelines address the use of the medications with potential cardiovascular benefit.
The American Diabetes Association (ADA) has released their annual Standards of Medical Care in Diabetes for 2018, highlighting several updated recommendations for diabetes care and management.
Top articles of the week from The American Journal of Pharmacy Benefits.
PD-L1-based immunotherapy observed to elicit long-lasting diabetes reversal in mice.
Diabetics using continuous glucose monitors were more aware of their blood sugar levels.
Top news of the day from across the healthcare landscape.
Top news of the day from across the health care landscape.
Patients with diabetes are significantly more likely to develop cardiovascular disease than nondiabetic patients.
The FDA issued approval to semaglutide injection (Ozempic) for type 2 diabetes.
The FDA has approved Novo Nordisk’s semaglutide injection (Ozempic), a glucagon-like peptide 1 (GLP-1) receptor agonist, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Between 10% and 20% of students in kindergarten through high school have chronic illness.
Nearly 700 million individuals around the world will develop diabetes by 2045, many of whom are undiagnosed.
Women with type 2 diabetes were 43% more likely to develop estrogen receptor negative breast cancer than patients without diabetes.
Top articles of the week from The American Journal of Pharmacy Benefits.
A look at last week's top stories in the world of pharmacy.
Patients with severe psoriasis were 64% more likely to develop diabetes than control patients.
Children and young adults with diabetes 8 times more likely to experience cardiovascular mortality.
It’s been more than 6 decades since Professor R. Keith Campbell, from Washington State University, was diagnosed with diabetes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
3
Darovasertib Plus Crizotinib Shows Striking Efficacy in HLA-A2–Negative Metastatic Uveal Melanoma, OptimUM-02 Results Show
4
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
5